NCT02429518View on ClinicalTrials.gov

Dedicated QT Study in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis

CompletedOBSERVATIONAL
Enrollment

42

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

June 6, 2017

Study Completion Date

March 6, 2018

Conditions
Mucocutaneous Leishmaniasis
Interventions
DRUG

Miltefosine

Trial Locations (1)

Unknown

Funderma, Santa Cruz

Sponsors
All Listed Sponsors
lead

Knight Therapeutics (USA) Inc

INDUSTRY